The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
Cesar Serrano-Garcia
No relevant relationships to disclose
Michael C. Heinrich
Consultant or Advisory Role - ARIAD; MolecularMD; Novartis; Pfizer
Stock Ownership - MolecularMD
Honoraria - Novartis; Onyx
Research Funding - Arog; Astex Therapeutics; Bayer; Novartis
Meijun Zhu
No relevant relationships to disclose
Chandrajit P. Raut
Honoraria - Novartis
Grant Eilers
No relevant relationships to disclose
Gloria Ravegnini
No relevant relationships to disclose
George D. Demetri
Consultant or Advisory Role - Bayer; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - Bayer; GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - Bayer (U)
Sebastian Bauer
Honoraria - Bayer; Novartis; Pfizer
Jonathan A. Fletcher
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Suzanne George
Consultant or Advisory Role - Bayer
Research Funding - Bayer; Novartis; Pfizer